MCID: CRY005
MIFTS: 58

Cryptococcosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Cryptococcosis

MalaCards integrated aliases for Cryptococcosis:

Name: Cryptococcosis 12 74 52 58 54 43 15 17 32
Infection by Cryptococcus Neoformans 71
Cryptococcus Neoformans Infection 12
Busse-Buschke's Disease 12
European Cryptococcosis 12
Cryptococcal Infection 12
Torulosis 12
Torula 12

Characteristics:

Orphanet epidemiological data:

58
cryptococcosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Cryptococcosis

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii.

MalaCards based summary : Cryptococcosis, also known as infection by cryptococcus neoformans, is related to cryptococcal meningitis and acquired immunodeficiency syndrome. An important gene associated with Cryptococcosis is SELL (Selectin L), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Fluconazole and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are fever and immunodeficiency

Wikipedia : 74 Cryptococcosis, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus... more...

Related Diseases for Cryptococcosis

Diseases related to Cryptococcosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 635)
# Related Disease Score Top Affiliating Genes
1 cryptococcal meningitis 32.9 PLB1 MBL2 IFNG CD8A CD4
2 acquired immunodeficiency syndrome 31.5 IFNG FCGR3A CD4 CCR6
3 meningitis 31.3 MBL2 IL4 IFNG FCGR2A
4 meningoencephalitis 31.3 PLB1 CD8A CD4 CCR6
5 cellulitis 31.3 CD8A CD4 CCR6
6 candidiasis 31.1 MBL2 IL4 IFNG CLEC7A
7 pulmonary tuberculosis 31.1 MBL2 IL4 IFNG
8 lymphopenia 31.1 SELL IL4 IFNG CCR6
9 lupus erythematosus 31.0 IFNG FCGR3B FCGR3A FCGR2A
10 immune deficiency disease 30.9 SELL MBL2 IL4 IFNG CD4 CCR6
11 sarcoidosis 1 30.9 IFNG CD8A CD4 CCR6
12 aspergillosis 30.9 MBL2 IL4 IFNG CLEC7A CCR6
13 tularemia 30.9 MBL2 CD8A CD4
14 lymphadenitis 30.9 IFNG CD4 CCR6
15 lymph node tuberculosis 30.8 IFNG CD4
16 chorioretinitis 30.8 IFNG CD8A CD4
17 histoplasmosis 30.8 IFNG CLEC7A CD8A CD4 CCR6
18 mucormycosis 30.8 IFNG CLEC7A CD4 CCR6
19 miliary tuberculosis 30.7 IFNG CD8A CD4
20 neuroretinitis 30.7 IFNG CD4
21 bacterial pneumonia 30.7 CD8A CD4 CCR6
22 penicilliosis 30.6 CLEC7A CD4
23 sporotrichosis 30.5 IFNG CLEC7A CD4
24 pneumocystosis 30.5 CLEC7A CLEC6A CD8A CD4 CCR6
25 allergic hypersensitivity disease 30.5 SELL IL4 IFNG CD4 CCR6
26 crohn's disease 30.4 IL4 IFNG CD4 CCR6
27 pneumonia 30.4 SELL MBL2 IL4 IFNG CD8A
28 coccidioidomycosis 30.4 MBL2 CLEC7A CLEC6A CD4 CCR6
29 esophageal candidiasis 30.4 CD8A CD4 CCR6
30 blastomycosis 30.4 CLEC7A CLEC6A CD8A CD4 CCR6
31 oral candidiasis 30.4 CLEC7A CLEC6A CD8A CD4 CCR6
32 hyper ige recurrent infection syndrome 1 30.3 CLEC7A CD4 CCR6
33 salmonellosis 30.3 IFNG CD8A CD4 CCR6
34 thrombocytopenia 30.3 SELL IL4 IFNG FCGR3A FCGR2A
35 exanthem 30.3 CD8A CD4 CCR6
36 epidermodysplasia verruciformis 1 30.3 CD8A CD4 CCR6
37 pleural disease 30.2 IFNG CD8A CD4 CCR6
38 collagen disease 30.1 IL4 CD8A CD4 CCR6
39 phaeohyphomycosis 30.1 CLEC7A CLEC6A
40 progressive multifocal leukoencephalopathy 30.1 CD8A CD4 CCR6
41 chickenpox 30.1 IL4 IFNG CD8A CD4 CCR6
42 allergic bronchopulmonary aspergillosis 30.1 MBL2 IL4 IFNG
43 invasive aspergillosis 30.1 MBL2 IFNG CLEC7A CLEC6A CD4 CCR6
44 combined t cell and b cell immunodeficiency 30.0 IL4 CD8A CD4 CCR6
45 t cell deficiency 30.0 SELL CD8A CD4 CCR6
46 central nervous system vasculitis 30.0 IFNG CD8A CD4 CCR6
47 pulmonary disease, chronic obstructive 30.0 IL4 CD8A CD4 CCR6
48 dermatophytosis 30.0 CLEC7A CLEC6A CD4 CCR6
49 temporal arteritis 30.0 IFNG CD8A CD4 CCR6
50 cholangitis, primary sclerosing 29.9 CD8A CD4 CCR6

Comorbidity relations with Cryptococcosis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcal Meningitis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcosis:



Diseases related to Cryptococcosis

Symptoms & Phenotypes for Cryptococcosis

Human phenotypes related to Cryptococcosis:

58 31 (show all 42)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
2 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
3 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
4 nodular pattern on pulmonary hrct 58 31 frequent (33%) Frequent (79-30%) HP:0025392
5 hydrocephalus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000238
6 behavioral abnormality 58 31 occasional (7.5%) Occasional (29-5%) HP:0000708
7 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
8 cerebral cortical atrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002120
9 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
10 respiratory distress 58 31 occasional (7.5%) Occasional (29-5%) HP:0002098
11 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
12 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
13 mental deterioration 58 31 occasional (7.5%) Occasional (29-5%) HP:0001268
14 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
15 meningitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001287
16 pneumonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002090
17 mediastinal lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100721
18 limb muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003690
19 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
20 systemic lupus erythematosus 58 31 occasional (7.5%) Occasional (29-5%) HP:0002725
21 nuchal rigidity 58 31 occasional (7.5%) Occasional (29-5%) HP:0031179
22 seizures 58 31 very rare (1%) Very rare (<4-1%) HP:0001250
23 blindness 58 31 very rare (1%) Very rare (<4-1%) HP:0000618
24 memory impairment 58 31 very rare (1%) Very rare (<4-1%) HP:0002354
25 osteomyelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002754
26 osteolysis 58 31 very rare (1%) Very rare (<4-1%) HP:0002797
27 ophthalmoplegia 58 31 very rare (1%) Very rare (<4-1%) HP:0000602
28 abnormal cranial nerve morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0001291
29 sepsis 58 31 very rare (1%) Very rare (<4-1%) HP:0100806
30 cerebral edema 58 31 very rare (1%) Very rare (<4-1%) HP:0002181
31 peritonitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002586
32 abnormal retinal morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0000479
33 prostatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0000024
34 abnormality of the optic nerve 58 31 very rare (1%) Very rare (<4-1%) HP:0000587
35 abnormality of the outer ear 58 31 very rare (1%) Very rare (<4-1%) HP:0000356
36 vitritis 58 31 very rare (1%) Very rare (<4-1%) HP:0011531
37 lymphoid leukemia 58 31 very rare (1%) Very rare (<4-1%) HP:0005526
38 abnormality of the eye 58 Occasional (29-5%)
39 abnormality of vision 58 Occasional (29-5%)
40 dyspnea 58 Occasional (29-5%)
41 neoplasm 58 Occasional (29-5%)
42 autoimmunity 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Cryptococcosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A
2 immune system MP:0005387 9.36 CCR6 CD4 CD8A CLEC6A CLEC7A FCGR2A

Drugs & Therapeutics for Cryptococcosis

Drugs for Cryptococcosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
2
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
3
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
4
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
5
Voriconazole Approved Phase 4 137234-62-9 71616
6
Zidovudine Approved Phase 4 30516-87-1 35370
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Hormone Antagonists Phase 4
14 Steroid Synthesis Inhibitors Phase 4
15 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
16 Hormones Phase 4
17 Antiparasitic Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Anti-Bacterial Agents Phase 4
20 Liposomal amphotericin B Phase 4
21 Cytochrome P-450 CYP3A Inhibitors Phase 4
22 Cytochrome P-450 CYP3A Inducers Phase 4
23 Anti-Retroviral Agents Phase 4
24 Antiviral Agents Phase 4
25 Reverse Transcriptase Inhibitors Phase 4
26 Anti-HIV Agents Phase 4
27 Micronutrients Phase 4
28 Vitamins Phase 4
29 Trace Elements Phase 4
30 Nutrients Phase 4
31 Ergocalciferols Phase 4
32 Calcium, Dietary Phase 4
33 Calciferol Phase 4
34 Vitamin D2 Phase 4
35
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
36
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
37
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
38
Isavuconazole Approved, Investigational Phase 3 241479-67-4
39
Sertraline Approved Phase 3 79617-96-2 68617
40 Pharmaceutical Solutions Phase 3
41
Hydroxyitraconazole Phase 3
42 Serotonin Uptake Inhibitors Phase 3
43 Neurotransmitter Agents Phase 3
44 Psychotropic Drugs Phase 3
45 Serotonin Agents Phase 3
46 Antidepressive Agents Phase 3
47
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
50
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
2 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
3 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
4 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
5 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
6 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
9 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034658 Phase 3 Posaconazole
10 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034632 Phase 3 Posaconazole oral suspension
11 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
12 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
13 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
14 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
15 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
16 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
18 A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection Withdrawn NCT03196921 Phase 1, Phase 2 Encochleated Amphotericin B
19 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
20 Multi-center Clinical Trial of Pulmonary Cryptococcosis in China Unknown status NCT02503449
21 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Unknown status NCT03267407
22 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection Completed NCT00001701
23 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
24 Special Investigation Of Fluconazole For Pediatric Subjects Completed NCT01680458 Fluconazole
25 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
26 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
27 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
28 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
29 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
30 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
31 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
32 Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection Completed NCT00002438 Itraconazole
33 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
34 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
35 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
36 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
37 Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole Completed NCT00309582
38 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
39 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
40 A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy Completed NCT00286767
41 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
42 AIDS-Associated Heart Disease -- Incidence and Etiology Completed NCT00005228
43 Cryptococcosis in Previously Healthy Adults Recruiting NCT00001352
44 AIDS Defining Opportunistic Infections in Naive HIV Cases Recruiting NCT03993093
45 Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models Recruiting NCT02015013
46 Vicente Ferrer HIV Cohort Study Recruiting NCT02454569
47 Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia Not yet recruiting NCT04033120

Search NIH Clinical Center for Cryptococcosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Itraconazole

Cochrane evidence based reviews: cryptococcosis

Genetic Tests for Cryptococcosis

Anatomical Context for Cryptococcosis

MalaCards organs/tissues related to Cryptococcosis:

40
Lung, T Cells, Testes, Liver, Skin, Bone, Brain

Publications for Cryptococcosis

Articles related to Cryptococcosis:

(show top 50) (show all 5001)
# Title Authors PMID Year
1
Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. 54 61
15776384 2005
2
Neurological worsening during treatment of an immunocompetent adult with Cryptococcus neoformans meningitis. 61
31993318 2020
3
Effects of CD4 cell count and antiretroviral therapy on mucocutaneous manifestations among HIV/AIDS patients in Yunnan, China. 61
31846069 2020
4
Cryptococcal antigenemia prevalence and clinical data in HIV-infected patients from the reference centre at INI-FIOCRUZ, Rio de Janeiro, Southeast of Brazil. 61
31715053 2020
5
Cryptococcosis. 61
32000285 2020
6
CRyptOcoccosis in Newcastle and the hUnTer (CRONUT) - An epidemiological study. 61
31501070 2020
7
Disseminated cryptococcosis with granuloma formation in idiopathic CD4 lymphocytopenia. 61
31345742 2020
8
Modulation of host immune status by cryptococcus co-infection during HIV-1 pathogenesis and its impact on CD+4 cell and cytokines environment. 61
31715319 2020
9
17-β-estradiol increases macrophage activity through activation of the GPER estrogen receptor and improves the response of female mice to Cryptococcus gattii. 61
32017324 2020
10
Antifungal activity of promethazine and chlorpromazine against planktonic cells and biofilms of Cryptococcus neoformans/Cryptococcus gattii complex species. 61
32016364 2020
11
Immunomodulatory activity of β-glucan-containing exopolysaccharides from Auricularia auricular in phagocytes and mice infected with Cryptococcus neoformans. 61
31095342 2020
12
Mass-forming hepatic cryptococcosis: a mimicker of metastatic tumors. 61
32036416 2020
13
Pulmonary cryptococcosis: Report of the first confirmed autochthonous case in Nepal. 61
31580849 2020
14
Lower Mortality Rates from Cryptococcosis in Women and Whites with Human Immunodeficiency Virus in the United States. 61
31664674 2020
15
Risk Factors Associated With Invasive Fungal Infections in Kidney Transplant Patients. 61
31836132 2020
16
Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. 61
31699504 2020
17
Epidemiological characteristics of cryptococcal meningoencephalitis associated with Cryptococcus neoformans var. grubii from HIV-infected patients in Madagascar: A cross-sectional study. 61
31929533 2020
18
Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases. 61
31986367 2020
19
Multifocal cryptococcal disease in an HIV-infected patient: from diagnostic pursuit to management peculiarities. 61
31937629 2020
20
MiR-30c-5p mediates inflammatory responses and promotes microglia survival by targeting eIF2α during Cryptococcus neoformans infection. 61
31958475 2020
21
Postoperative Antifungal Treatment of Pulmonary Cryptococcosis in Non-HIV-Infected and Non-Transplant-Recipient Patients: A Report of 110 Cases and Literature Review. 61
32010733 2020
22
Vaccines and Protective Immune Memory against Cryptococcosis. 61
32009111 2020
23
Vertebral cryptococcosis: An uncommon cause of a paravertebral mass. 61
31994665 2020
24
CARD9 Is Required for Classical Macrophage Activation and the Induction of Protective Immunity against Pulmonary Cryptococcosis. 61
31911495 2020
25
An exceptional case report of disseminated cryptococcosis in a hitherto immunocompetent patient. 61
31967211 2020
26
Pulmonary Cryptococcosis: comparison of Cryptococcal antigen detection and radiography in Immunocompetent and Immunocompromised patients. 61
32000709 2020
27
Solitary Pulmonary Nodule as a Form of Presentation of Cryptococcosis in a Renal Transplant Recipient. 61
31926752 2020
28
N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis. 61
31919505 2020
29
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report. 61
31914067 2020
30
Pulmonary Cryptococcosis in a Nurse Initially Suspected of Having Pulmonary Tuberculosis. 61
31924748 2020
31
Iron sequestration by Cryptococcus neoformans in an HIV-positive woman with disseminated cryptococcosis. 61
31991485 2020
32
Clinical features of pulmonary cryptococcosis in thin-section CT in immunocompetent and non-AIDS immunocompromised patients. 61
31587180 2020
33
Comparing immunochromatography with latex antigen agglutination testing for the diagnosis of cryptococcosis in cats, dogs and koalas. 61
31220311 2020
34
Cryptococcal Antigen Testing in an Integrated Medical System: Eastern Wisconsin. 61
32002448 2020
35
Clinical Significance of Low Serum Cryptococcal Antigen Titers by Lateral Flow Assay in Immunocompromised Patients: a Retrospective Case-Control Study. 61
31723013 2020
36
Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex. 61
31750814 2020
37
New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans In Vitro and In Vivo. 61
31791946 2020
38
CT Halo sign: A systematic review. 61
32007819 2020
39
Pyrifenox, an ergosterol inhibitor, differentially affects Cryptococcus neoformans and Cryptococcus gattii. 61
31915833 2020
40
The Diagnostic Laboratory Hub: A New Health Care System Reveals the Incidence and Mortality of Tuberculosis, Histoplasmosis, and Cryptococcosis of PWH in Guatemala. 61
31915715 2020
41
Identification of off-patent drugs that show synergism with Amphotericin B or that present antifungal action against Cryptococcus neoformans and Candida spp. 61
31988099 2020
42
Effect of non-antifungal agrochemicals on the pathogenic fungus Cryptococcus gattii. 61
30888411 2020
43
[DISSEMINATED CRYPTOCOCCOSIS IN A LIVER TRANSPLANT RECIPIENT DIAGNOSED BY TZANCK SMEAR]. 61
31930800 2020
44
A Multicenter, Longitudinal Cohort Study of Cryptococcosis in Human Immunodeficiency Virus-negative People in the United States. 61
30855688 2020
45
Immune reconstitution inflammatory syndrome in the lung in non-human immunodeficiency virus patients. 61
31791908 2020
46
Disseminated Cryptococcosis revealed by transverse myelitis in Immunocompetent patient: a case report and review of the literature. 61
31924167 2020
47
Did This Cryptococcosis Patient Have HIV Coinfection? 61
31391390 2019
48
[Imaging Findings of Pulmonary Cryptococcosis]. 61
31907136 2019
49
A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans. 61
31822582 2019
50
Genotypic diversity in clinical and environmental isolates of Cryptococcus neoformans from India using multilocus microsatellite and multilocus sequence typing. 61
31820495 2019

Variations for Cryptococcosis

Expression for Cryptococcosis

Search GEO for disease gene expression data for Cryptococcosis.

Pathways for Cryptococcosis

Pathways related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 SELL MBL2 IL4 IFNG FCGR3B FCGR3A
2
Show member pathways
12.08 IL4 IFNG FCGR3B FCGR3A FCGR2A
3 12.02 IFNG FCGR3B FCGR3A FCGR2A CLEC7A
4 11.92 IFNG FCGR3B FCGR3A FCGR2A
5 11.9 MBL2 FCGR3B FCGR3A FCGR2A CLEC7A
6
Show member pathways
11.85 IL4 IFNG CD8A CD4
7
Show member pathways
11.76 IL4 IFNG FCGR3B FCGR3A FCGR2A
8 11.74 IL4 CD8A CD4
9 11.74 MBL2 FCGR3B FCGR3A FCGR2A
10 11.7 FCGR3B FCGR3A FCGR2A
11 11.65 FCGR3B FCGR2A CLEC7A
12 11.6 SELL IFNG CD8A CD4
13 11.46 IL4 IFNG CD8A CD4 CCR6
14 11.38 IL4 IFNG CD4
15 11.2 IL4 IFNG FCGR3B FCGR3A FCGR2A
16 11.16 SELL IL4 IFNG FCGR2A CD8A CD4
17 11.12 IL4 IFNG CD4

GO Terms for Cryptococcosis

Cellular components related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 SELL FCGR3A CD8A CD4 CCR6

Biological processes related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.76 SELL IL4 FCGR3A CD8A
2 hormone-mediated signaling pathway GO:0009755 9.58 CGB8 CGB7 CGB3
3 positive regulation of phagocytosis GO:0050766 9.5 MBL2 IFNG CLEC7A
4 immune response GO:0006955 9.5 IL4 IFNG FCGR3B FCGR3A CD8A CD4
5 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.49 CLEC7A CD4
6 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL4 IFNG
7 positive regulation of killing of cells of other organism GO:0051712 9.43 IFNG CLEC7A
8 neuroinflammatory response GO:0150076 9.37 IL4 IFNG
9 female gamete generation GO:0007292 9.33 CGB8 CGB7 CGB3
10 positive regulation of cellular respiration GO:1901857 9.26 IL4 IFNG
11 T cell activation GO:0042110 8.92 IL4 CLEC7A CD8A CD4

Molecular functions related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.26 SELL MBL2 CLEC7A CLEC6A
2 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A

Sources for Cryptococcosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....